Table 3. HAT Gene Mutations in B- and T-cell Malignancies.
| HAT | Percent of B- and T- cell lines with HAT gene mutations from CCLE [96] | Percent of HAT gene mutations in leukemia/lymphoma from select genome-wide studies |
|---|---|---|
| ATF2 | 0.6 | |
| CBP | 13.3 | DLBCL, 19% (443) [88, 91-93, 180, 181] FL, 50% (52) [92, 93], Relapsed ALL, 18% (71) [182] |
| p300 | 10.5 | DLBCL, 11% (546) [88, 91-93, 106, 180] FL, 19% (52) [92, 93] |
| TIP60 | 0 | DLBCL, 2% (49) [180] |
| MOZ | 7.7 | DLBCL, 4% (53) [181] |
| MORF | 27.6 | |
| HBO1 | 0.6 | |
| NCOA1 | 2.2 | |
| NCOA2 | 3.9 | DLBCL, 2% (53) [181] |
| NCOA3 | 39.8 | DLBCL, 4% (53) [181] |
| CLOCK | 0 | DLBCL, 2% (102) [180, 181] |
| TAF1 | 3.3 | FL, 10% (39) [93] DLBCL, 5% (102) [180, 181] |
Percentage of cell lines mutated in CCLE (Cancer Cell Line Encyclopedia) indicates the percentage of 181 hematopoietic and lymphoid cell lines that had a mutation in the indicated HAT gene. DLBCL and FL genomic studies indicate the percentage of cases reported to have mutations in the indicated HAT gene in either DLBCL (diffuse large B-cell lymphoma) or FL (follicular lymphoma) patient samples and/or cell lines, with the total number of samples analyzed shown in parentheses.